FollowMyHealth Patient Portal

Faculty Physicians

Joel Picus, MD

Professor, Medicine
Division of Oncology - Medical Oncology
Section, Medical and Molecular Oncology

Specialty Areas

Oncology
Hematology
Gastrointestinal Oncology
Hepatobiliary Pancreatic Cancer
Colon and Rectal Cancer
Genitourinary Oncology
Pancreatic Cancer

Board Certifications

Hematology
Internal Medicine
Oncology

Areas of Clinical Interest

Diagnosis of tumors, renal cell carcinoma, RCC, pancreatic cancer, pancreas, cholangiocarcinoma, prostate cancer, colon cancer, bladder cancer, rectal carcinoma, immunotherapy, chemotherapy, GI cancer, GU cancer

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-747-9281
Fax: 314-362-7086

Siteman Cancer Center - South County

5225 MidAmerica Plaza
St. Louis, MO 63129

Office Phone: 314 747 1171

Education

Education

Fellowship: Hematology and Oncology, Cancer Research Institute, University of California, San Francisco, CA 1991
Residency: Internal Medicine, Duke University Medical Center 1987
Medical Degree: Harvard Medical School, Boston, MA 1984
B.S.: Electrical Engineering, University of Illinois, Urbana, IL 1979
B.A.: Biology, University of Illinois, Urbana, IL 1979

Publication & Research

Publication & Research

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS
N Engl J Med. 2015 Aug 20; 373(8)737-46. doi: 10.1056/NEJMoa1503747.

PMID:
    26244877
    [PubMed - indexed for MEDLINE]
Related citations


Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.
Merchan JR, Qin R, Pitot H, Picus J, Liu G, Fitch T, Maples WJ, Flynn PJ, Fruth BF, Erlichman C
Cancer Chemother Pharmacol. 2015 Mar; 75(3)485-93. doi: 10.1007/s00280-014-2668-5.

PMID:
    25556030
    [PubMed - indexed for MEDLINE]
Related citations


Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC
PLoS One. 2014; 9(9)e107424. doi: 10.1371/journal.pone.0107424.

PMID:
    25232828
    [PubMed - indexed for MEDLINE]
Related citations


A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.
Wang-Gillam A, Thakkar N, Lockhart AC, Williams K, Baggstrom M, Naughton M, Suresh R, Ma C, Tan B, Lee W, Jiang X, Mwandoro T, Trull L, Belanger S, Creekmore AN, Gao F, Fracasso PM, Picus J
Cancer Chemother Pharmacol. 2014 Aug; 74(2)419-26. doi: 10.1007/s00280-014-2493-x.

PMID:
    24916546
    [PubMed - indexed for MEDLINE]
Related citations


Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer.
Myerson RJ, Tan B, Hunt S, Olsen J, Birnbaum E, Fleshman J, Gao F, Hall L, Kodner I, Lockhart AC, Mutch M, Naughton M, Picus J, Rigden C, Safar B, Sorscher S, Suresh R, Wang-Gillam A, Parikh P
Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4)829-36. doi: 10.1016/j.ijrobp.2013.12.028.

PMID:
    24606849
    [PubMed - indexed for MEDLINE]
Related citations


Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.
Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI, COU-AA-301 Investigators
Eur J Cancer. 2013 Nov; 49(17)3648-57. doi: 10.1016/j.ejca.2013.07.144.

PMID:
    23973186
    [PubMed - indexed for MEDLINE]
Related citations


A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.
Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U
Clin Genitourin Cancer. 2013 Dec; 11(4)477-83. doi: 10.1016/j.clgc.2013.05.005.

PMID:
    23891158
    [PubMed - indexed for MEDLINE]
Related citations


A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.
Rathkopf DE, Picus J, Hussain A, Ellard S, Chi KN, Nydam T, Allen-Freda E, Mishra KK, Porro MG, Scher HI, Wilding G
Cancer Chemother Pharmacol. 2013 Sep; 72(3)537-44. doi: 10.1007/s00280-013-2224-8.

PMID:
    23820963
    [PubMed - indexed for MEDLINE]
Related citations


Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.
Arcaroli J, Quackenbush K, Dasari A, Powell R, McManus M, Tan AC, Foster NR, Picus J, Wright J, Nallapareddy S, Erlichman C, Hidalgo M, Messersmith WA
Cancer Med. 2012 Oct; 1(2)207-17. doi: 10.1002/cam4.27.

PMID:
    23342270
    [PubMed - indexed for MEDLINE]
Related citations


A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.
Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Craig Lockhart A, Naughton MJ, Pluard TJ, Brenin CM, Picus J, Creekmore AN, Mwandoro T, Yarde ER, Reed J, Ebbert M, Bernard PS, Watson M, Doyle LA, Dancey J, Piwnica-Worms H, Fracasso PM
Breast Cancer Res Treat. 2013 Jan; 137(2)483-92. doi: 10.1007/s10549-012-2378-9.

PMID:
    23242585
    [PubMed - indexed for MEDLINE]
Related citations


Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone.
Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR
Clin Cancer Res. 2013 Jan 1; 19(1)215-24. doi: 10.1158/1078-0432.CCR-12-2605.

PMID:
    23136195
    [PubMed - indexed for MEDLINE]
Related citations


Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer.
Aggarwal C, Meropol NJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Cohen SJ
Ann Oncol. 2013 Feb; 24(2)420-8. doi: 10.1093/annonc/mds336.

PMID:
    23028040
    [PubMed - indexed for MEDLINE]
Related citations


Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS, COU-AA-301 Investigators
Lancet Oncol. 2012 Oct; 13(10)983-92. doi: 10.1016/S1470-2045(12)70379-0.

PMID:
    22995653
    [PubMed - indexed for MEDLINE]
Related citations


Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, Gao F, Linehan D, Wang-Gillam A
JOP. 2012 Sep 10; 13(5)497-501. doi: 10.6092/1590-8577/913.

PMID:
    22964956
    [PubMed - indexed for MEDLINE]
Related citations


Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.
Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SC, To KF, Tao Q, Ma BB, Chan AW, Tong JH, Erlichman C, Chan AT, Goh BC
J Clin Oncol. 2012 Sep 20; 30(27)3361-7. doi: 10.1200/JCO.2011.41.2395.

PMID:
    22915658
    [PubMed - indexed for MEDLINE]
Related citations


Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH
J Clin Oncol. 2012 Nov 10; 30(32)3998-4003. doi: 10.1200/JCO.2011.39.5558.

PMID:
    22915652
    [PubMed - indexed for MEDLINE]
Related citations


Increased survival with enzalutamide in prostate cancer after chemotherapy.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, AFFIRM Investigators
N Engl J Med. 2012 Sep 27; 367(13)1187-97.

PMID:
    22894553
    [PubMed - indexed for MEDLINE]
Related citations


A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma.
Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, Tan B, Hawkins WG
Invest New Drugs. 2013 Jun; 31(3)707-13. doi: 10.1007/s10637-012-9866-y.

PMID:
    22864469
    [PubMed - indexed for MEDLINE]
Related citations


Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ
Oncologist. 2012; 17(1)13. doi: 10.1634/theoncologist.2011-0253.

PMID:
    22210086
    [PubMed - indexed for MEDLINE]
Related citations


Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ, Cancer and Leukemia Group B
Cancer. 2012 Sep 1; 118(17)4139-47. doi: 10.1002/cncr.26732.

PMID:
    22180287
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following earned financial interests during calendar year 2014.

Company Name: Novo-Nordisc/Quintiles

Royalties:

Equity: No

Consulting/Advisory Board: $25,001 - $50,000

Speaker Fees:

Reporting Date: May 01, 2015